Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka

Yo Ichi Yamashita, Ken Sirabe, Ken Kawabe, Nao Fujimori, Terumasa Hisano, Yoshinobu Okabe, Takumi Akiyama, Toshiharu Ueki, Hikoyuki Horiuchi, Hiroya Yamaguchi, Tetsuhide Ito, Hideya Suga, Akihiro Funakosi

研究成果: ジャーナルへの寄稿記事

抄録

The standard chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers is considered gemcitabine plus cisplatin (Gc) on the basis of favorable results reported in the ABC-02 study from the UK and the BT22 study from Japan. However, the GC cohort of the BT22 study consisted of only 42 patients, and we considered it necessary to confirm the effectiveness and safety of GC chemotherapy in a multicenter prospective observational study in Fukuoka. Thirty- seven patients were enrolled in this study, including two patients with recurrent disease. The median patient age was 67.5 years (range, 43-84 years). Twelve patients had intrahepatic cholangiocarcinoma, 13 patients had extrahepatic cholangiocarcinoma, and 12 patients had gallbladder cancer. The median survival time (MST) was 14.9 months, the 1-year survival rate was 54.5%, and the median progression free survival (PFS) was 7.7 months. No chemotherapy-related deaths occurred, and Grade 3/4 adverse events were mainly hematological events including leucopenia in 13 (35.1%) patients and neutropenia in 12 (32.4%). The MST, 1-year survival rate, median PFS, and rate of Grade 3/4 adverse events in our study were similar to those of the BT22 study. In conclusion, this multicenter prospective observational study confirms the effectiveness and safety of GC chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers.

元の言語英語
ページ(範囲)1185-1189
ページ数5
ジャーナルJapanese Journal of Cancer and Chemotherapy
42
発行部数10
出版物ステータス出版済み - 10 1 2015

Fingerprint

gemcitabine
Biliary Tract Neoplasms
Cisplatin
Observational Studies
Prospective Studies
Drug Therapy
Cholangiocarcinoma
Survival Rate
Disease-Free Survival
Gallbladder Neoplasms
Safety
Survival
Leukopenia
Neutropenia

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka. / Yamashita, Yo Ichi; Sirabe, Ken; Kawabe, Ken; Fujimori, Nao; Hisano, Terumasa; Okabe, Yoshinobu; Akiyama, Takumi; Ueki, Toshiharu; Horiuchi, Hikoyuki; Yamaguchi, Hiroya; Ito, Tetsuhide; Suga, Hideya; Funakosi, Akihiro.

:: Japanese Journal of Cancer and Chemotherapy, 巻 42, 番号 10, 01.10.2015, p. 1185-1189.

研究成果: ジャーナルへの寄稿記事

Yamashita, YI, Sirabe, K, Kawabe, K, Fujimori, N, Hisano, T, Okabe, Y, Akiyama, T, Ueki, T, Horiuchi, H, Yamaguchi, H, Ito, T, Suga, H & Funakosi, A 2015, 'Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka', Japanese Journal of Cancer and Chemotherapy, 巻. 42, 番号 10, pp. 1185-1189.
Yamashita, Yo Ichi ; Sirabe, Ken ; Kawabe, Ken ; Fujimori, Nao ; Hisano, Terumasa ; Okabe, Yoshinobu ; Akiyama, Takumi ; Ueki, Toshiharu ; Horiuchi, Hikoyuki ; Yamaguchi, Hiroya ; Ito, Tetsuhide ; Suga, Hideya ; Funakosi, Akihiro. / Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka. :: Japanese Journal of Cancer and Chemotherapy. 2015 ; 巻 42, 番号 10. pp. 1185-1189.
@article{173a723b43e5461d9ff173d1c493f8c3,
title = "Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka",
abstract = "The standard chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers is considered gemcitabine plus cisplatin (Gc) on the basis of favorable results reported in the ABC-02 study from the UK and the BT22 study from Japan. However, the GC cohort of the BT22 study consisted of only 42 patients, and we considered it necessary to confirm the effectiveness and safety of GC chemotherapy in a multicenter prospective observational study in Fukuoka. Thirty- seven patients were enrolled in this study, including two patients with recurrent disease. The median patient age was 67.5 years (range, 43-84 years). Twelve patients had intrahepatic cholangiocarcinoma, 13 patients had extrahepatic cholangiocarcinoma, and 12 patients had gallbladder cancer. The median survival time (MST) was 14.9 months, the 1-year survival rate was 54.5{\%}, and the median progression free survival (PFS) was 7.7 months. No chemotherapy-related deaths occurred, and Grade 3/4 adverse events were mainly hematological events including leucopenia in 13 (35.1{\%}) patients and neutropenia in 12 (32.4{\%}). The MST, 1-year survival rate, median PFS, and rate of Grade 3/4 adverse events in our study were similar to those of the BT22 study. In conclusion, this multicenter prospective observational study confirms the effectiveness and safety of GC chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers.",
author = "Yamashita, {Yo Ichi} and Ken Sirabe and Ken Kawabe and Nao Fujimori and Terumasa Hisano and Yoshinobu Okabe and Takumi Akiyama and Toshiharu Ueki and Hikoyuki Horiuchi and Hiroya Yamaguchi and Tetsuhide Ito and Hideya Suga and Akihiro Funakosi",
year = "2015",
month = "10",
day = "1",
language = "English",
volume = "42",
pages = "1185--1189",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "10",

}

TY - JOUR

T1 - Gemcitabine in combination with cisplatin in patients with unresectable advanced or recurrent biliary tract cancer-a multicenter prospective observational study in Fukuoka

AU - Yamashita, Yo Ichi

AU - Sirabe, Ken

AU - Kawabe, Ken

AU - Fujimori, Nao

AU - Hisano, Terumasa

AU - Okabe, Yoshinobu

AU - Akiyama, Takumi

AU - Ueki, Toshiharu

AU - Horiuchi, Hikoyuki

AU - Yamaguchi, Hiroya

AU - Ito, Tetsuhide

AU - Suga, Hideya

AU - Funakosi, Akihiro

PY - 2015/10/1

Y1 - 2015/10/1

N2 - The standard chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers is considered gemcitabine plus cisplatin (Gc) on the basis of favorable results reported in the ABC-02 study from the UK and the BT22 study from Japan. However, the GC cohort of the BT22 study consisted of only 42 patients, and we considered it necessary to confirm the effectiveness and safety of GC chemotherapy in a multicenter prospective observational study in Fukuoka. Thirty- seven patients were enrolled in this study, including two patients with recurrent disease. The median patient age was 67.5 years (range, 43-84 years). Twelve patients had intrahepatic cholangiocarcinoma, 13 patients had extrahepatic cholangiocarcinoma, and 12 patients had gallbladder cancer. The median survival time (MST) was 14.9 months, the 1-year survival rate was 54.5%, and the median progression free survival (PFS) was 7.7 months. No chemotherapy-related deaths occurred, and Grade 3/4 adverse events were mainly hematological events including leucopenia in 13 (35.1%) patients and neutropenia in 12 (32.4%). The MST, 1-year survival rate, median PFS, and rate of Grade 3/4 adverse events in our study were similar to those of the BT22 study. In conclusion, this multicenter prospective observational study confirms the effectiveness and safety of GC chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers.

AB - The standard chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers is considered gemcitabine plus cisplatin (Gc) on the basis of favorable results reported in the ABC-02 study from the UK and the BT22 study from Japan. However, the GC cohort of the BT22 study consisted of only 42 patients, and we considered it necessary to confirm the effectiveness and safety of GC chemotherapy in a multicenter prospective observational study in Fukuoka. Thirty- seven patients were enrolled in this study, including two patients with recurrent disease. The median patient age was 67.5 years (range, 43-84 years). Twelve patients had intrahepatic cholangiocarcinoma, 13 patients had extrahepatic cholangiocarcinoma, and 12 patients had gallbladder cancer. The median survival time (MST) was 14.9 months, the 1-year survival rate was 54.5%, and the median progression free survival (PFS) was 7.7 months. No chemotherapy-related deaths occurred, and Grade 3/4 adverse events were mainly hematological events including leucopenia in 13 (35.1%) patients and neutropenia in 12 (32.4%). The MST, 1-year survival rate, median PFS, and rate of Grade 3/4 adverse events in our study were similar to those of the BT22 study. In conclusion, this multicenter prospective observational study confirms the effectiveness and safety of GC chemotherapy for the treatment of unresectable advanced and recurrent biliary tract cancers.

UR - http://www.scopus.com/inward/record.url?scp=84962311074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962311074&partnerID=8YFLogxK

M3 - Article

C2 - 26489546

AN - SCOPUS:84962311074

VL - 42

SP - 1185

EP - 1189

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 10

ER -